2018
DOI: 10.1096/fasebj.2018.32.1_supplement.553.11
|View full text |Cite
|
Sign up to set email alerts
|

Dopamine Cell Loss within the Nigrostriatal Pathway Due to Oxidative Stress from Chronic Methylphenidate

Abstract: Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 11% of children in the U.S. alone. Methylphenidate (MPH) is the most commonly prescribed drug for the treatment of ADHD. MPH acts by blocking dopamine (DA) transporters and norepinephrine (NE) transporters, preventing the reuptake of these catecholamines following release. Many children receive MPH from childhood to early adulthood; yet, most of the scientific literature focuses on understanding short‐term consequences o… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles